Phio Pharmaceuticals (PHIO) Income from Continuing Operations (2011 - 2026)

Phio Pharmaceuticals (PHIO) has reported Income from Continuing Operations for 16 consecutive years, with -$4.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Income from Continuing Operations fell 91.04% year-over-year to -$4.1 million; the trailing twelve-month figure through Jun 2026 stood at -$12.7 million (down 75.78% YoY), and the FY2025 full-year result was -$11.4 million, down 52.29% from the prior year.
• Income from Continuing Operations eased to -$4.1 million in Q2 2026 per PHIO's latest filing, from -$4.0 million in the prior quarter.
• Across five years, Income from Continuing Operations topped out at -$1.5 million in Q3 2024 and bottomed at -$5.1 million in Q4 2025.
• Historically, Income from Continuing Operations has averaged -$2.7 million across 5 years, with a median of -$2.5 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations jumped 45.1% in 2024, then sank 158.1% in 2025.
• Over 5 years, Income from Continuing Operations stood at -$2.7 million in 2022, then jumped by 30.44% to -$1.9 million in 2023, then fell by 3.69% to -$2.0 million in 2024, then plunged by 158.1% to -$5.1 million in 2025, then climbed by 18.58% to -$4.1 million in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered -$4.1 million, -$4.0 million, and -$5.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.